ISB 2001

A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects With Relapsed/Refractory Multiple Myeloma

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
80 patients (estimated)
Sponsors
Ichnos Sciences SA
Tags
T Cell, B-Cell Maturation Antigen (BCMA), CD38
Trial Type
Treatment
Last Update
1 week ago
SparkCures ID
1985
NCT Identifier
NCT05862012

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.